Loading company…
Spiral Therapeutics develops inner ear drug delivery treatments for Ménière's disease and other balance and hearing disorders.
Founded in 2016 and headquartered in South San Francisco, US, Spiral Therapeutics develops drug delivery systems for inner ear disorders, mainly Ménière's disease. Its lead product, SPT-2101, is a sustained-release steroid formulation delivered through the Minimally Invasive Cochlear System (MICS). CEO Hugo Peris leads the company, which has raised USD 10.90 mn in total, including a Series A round on August 30, 2023, co-led by Catalio Capital Management, Humboldt Fund and Savoir Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in